Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with alzheimer's disease: A randomized, double blind, placebo controlled withdrawal trial

Journal of Alzheimer's Disease

Volumn 26, Issue 2, 2011, Pages 211-220

  Scarpini, Elio ^a   Bruno, Giuseppe ^b   Zappalà, Giuseppe ^c   Adami, Marina ^d   Richarz, Ute ^e   Gaudig, Maren ^f   Jacobs, Adam ^g   Schäuble, Barbara ^h  

^a UNIVERSITY OF MILAN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c GARIBALDI HOSPITAL   (Italy)

^d Janssen Cilag SpA Italia   (Italy)

^e Global Medical Affairs   (Switzerland)

^f Health Economics and Reimbursement   (Germany)

^g Dianthus Medical Limited   (United Kingdom)

^h LEMEA Medical Affairs   (Germany)

Author keywords

ADAS cog; Alzheimer's disease therapy; cognitive; galantamine; long term treatment; withdrawal design

Indexed keywords

GALANTAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MENTAL PATIENT; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

EID: 80052793008     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110134     Document Type: Article

References (10)

1. Loy C, Schneider L (2006) Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev, CD001747.
2. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y (2004) Long-term outcomes of galantamine treatment in patients with Alzheimer's disease. Am J Geriatr Psychiatry 12, 473-482. (Pubitemid 39181062)
3. Rockwood K, Dai D, Mitnitski A (2008) Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry 23, 207-214. (Pubitemid 351308502)
4. Institut fuer Qualitaet und Wirtschaftlichkeit im Gesund-heitswesen (IQWiG) (2007) Cholinesterase inhibitors in Alzheimer's disease-final report. https://www.iqwig.de/; Accessed April 27, 2011.
5. Feldman HH, Pirttila T, Dartigues JF, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, Kavanagh S (2009) Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovas-cular disease. Int J Geriatr Psychiatry 24, 479-488.
6. Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group (2004) Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 17, 29-34. (Pubitemid 37499964)
7. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, GAL-INT-6 Study Group (2003) An open label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 25, 1765-1782. (Pubitemid 36801947)
8. Pirttilä T, Wilcock G, Truyen L, Damaraju CV (2004) Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 11, 734-741. (Pubitemid 39556753)
9. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin JA, Battisti WP, Kavanagh S (2009) Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand 119, 22-31.
10. Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapicchio P, Senin U, Trabucchi M, Mussico M (2005) Guidelines for the treatment of Alzheimer's disease from the Italian association of psychogeriatrics. Drugs Aging 22 (Suppl 1), 1-26. (Pubitemid 41565869)